BiotechTube

Pegylated Interferon-α2b

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Aug 11, 2020 → Jun 21, 2021

NCT ID
NCT04480138

About Pegylated Interferon-α2b

Pegylated Interferon-α2b is a phase 2 stage product being developed by Zydus Lifesciences for Covid19. The current trial status is terminated. This product is registered under clinical trial identifier NCT04480138. Target conditions include Covid19.

What happened to similar drugs?

4 of 16 similar drugs in Covid19 were approved

Approved (4) Terminated (5) Active (9)
✅Icosapent ethylAmarin CorporationApproved
✅bamlanivimabEli LillyApproved
✅COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)SanofiApproved
✅Moderna mRNA-1273 COVID-19 vaccine + Pfizer BNT162b2 COVID-19 vaccineAllergy TherapeuticsApproved
❌AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
❌BaricitinibEli LillyPhase 3
🔄LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04480138Phase 2Terminated

Competing Products

20 competing products in Covid19

See all competitors
ProductCompanyStageHype Score
AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
29
Favipiravir + NitazoxanideStrides PharmaPhase 2
35
Icosapent ethylAmarin CorporationApproved
25
GX-03 + Petrolatum ointmentTurn TherapeuticsPhase 2
25
Cytotoxic T LymphocytesTevogen BioPhase 1
19
DS-5670a + PlaceboDaiichi SankyoPhase 1/2
32
BaricitinibEli LillyPhase 3
32
LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3
40
bamlanivimabEli LillyApproved
35
1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222AstraZenecaPhase 1
25
Sacubitril / Valsartan Oral Tablet [Entresto] + PlaceboNovartisPhase 1/2
32
PirfenidoneRochePre-clinical
26
Remdesivir + Remdesivir Placebo + CorticosteroidGilead SciencesPhase 3
40
RemdesivirGilead SciencesPre-clinical
26
Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + CorticosteroidGilead SciencesPhase 3
40
anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)PfizerPhase 3
36
Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 VaccinePfizerPre-clinical
26
Tofacitinib 10 mg + PlaceboPfizerPhase 3
40
BNT162b2PfizerPhase 2
35
Anakinra + 0.9% SalineSwedish Orphan BiovitrumPhase 2
27